PDE7 as a Precision Target: Bridging Disease Modulation and Potential PET Imaging for Translational Medicine

Figures

• 

  1. PDE7 in cAMP signaling, therapeutic targeting, and PET imaging potential. (A) PKA activation via cAMP binding. (B) PDE7 regulates cAMP-PKA signaling, influencing immune and neurological functions. (C) Structural optimization for improved bone mineral density (BMD). (D) PDE7 as a promising PET imaging target due to specific expression and translational potential.

• 

  2. Docking conformations of (a) compound 13 and (b) compound 14, where the methyl group is replaced with a cyclopropyl group for improved binding. The dashed circle highlights an unoccupied space near the methyl group in compound 13, indicating a potential site for structural optimization to enhance PDE7A selectivity and potency. Reproduced with permission from ref . Copyright 2024 American Chemical Society.

• 

  3. Evaluation of PDE7A-selective inhibitor 26 on Bone Mineral Density (BMD). The chemical structure of compound 26 is shown, along with its high selectivity for PDE7A (IC50 = 0.0037 μM) over PDE7B (IC50 = 0.20 μM, 54-fold selectivity). The bar graph illustrates the dose-dependent increase in BMD following administration of compound 26 (3, 10, and 30 mg/kg) compared to the vehicle control. Reproduced with permission from ref . Copyright 2024 American Chemical Society.